Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
暂无分享,去创建一个
S. Lonial | P. Richardson | Shaji K. Kumar | N. Callander | R. Orlowski | J. Zonder | E. Faber | L. Wagner | P. Kapoor | A. Cohen | S. Rajkumar | A. Menter | T. Parker | S. Jacobus | A. Rosenberg | B. Parsons | M. Weiss | K. Anderson | Pankaj Kumar | Xuezhong Yang | Avina K Singh | Terri L. Parker